Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aggressive natural killer cell leukemia/lymphoma

S Dunkley1, J Gibson, N Mackinlay

  • 1Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia.

Pathology
|June 27, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics.

Bone marrow transplantation·2020
Same author

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

Leukemia·2016
Same author

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study.

Leukemia·2016
Same author

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade.

Leukemia·2016
Same author

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group.

Leukemia·2015
Same author

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Leukemia·2015
Same journal

Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

Pathology·2026
Same journal

Cribriform intraductal carcinoma of the prostate may have a greater prognostic impact even than Gleason grade 5 conventional prostatic adenocarcinoma.

Pathology·2026
Same journal

Bordetella pertussis: emerging epidemiology, diagnosis and management.

Pathology·2026
Same journal

Development and validation of a real-time polymerase chain reaction for the detection of Haycocknema perplexum.

Pathology·2026
Same journal

Recent advances in the understanding of TP53 in haematological malignancies.

Pathology·2026
Same journal

Concurrent renal amyloid light chain amyloidosis, light chain crystalline podocytopathy and light chain proximal tubulopathy: a case report.

Pathology·2026
See all related articles

A rapidly progressing natural killer (NK) cell leukemia/lymphoma was diagnosed in a 32-year-old male presenting with fever and enlarged organs. Despite aggressive symptoms, the disease proved rapidly fatal within five days.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Natural killer (NK) cell malignancies are rare lymphoid neoplasms.
  • Distinguishing aggressive NK cell leukemia/lymphoma from other lymphoid disorders can be challenging.

Observation:

  • A 32-year-old male presented with acute onset of fever, significant hepatosplenomegaly, and lymphadenopathy.
  • Clinical presentation suggested a rapidly aggressive systemic illness.

Findings:

  • Peripheral blood and bone marrow examinations revealed morphological and immunophenotypic characteristics consistent with NK cell leukemia/lymphoma.
  • The immunophenotype confirmed the neoplastic proliferation of NK cells.

Implications:

  • This case highlights the aggressive nature and rapid progression possible in NK cell leukemia/lymphoma.

Related Experiment Videos

  • Early recognition and diagnosis are crucial for potential therapeutic interventions, though prognosis remains poor in rapidly progressive forms.
  • Further research into the pathogenesis and treatment of aggressive NK cell malignancies is warranted.